Clinicopathologic risk factors of radioactive iodine therapy based on response assessment in patients with differentiated thyroid cancer: a multicenter retrospective cohort study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwon, Seong Young | - |
dc.contributor.author | Lee, Sang-Woo | - |
dc.contributor.author | Kong, Eun Jung | - |
dc.contributor.author | Kim, Keunyoung | - |
dc.contributor.author | Kim, Byung Il | - |
dc.contributor.author | Kim, Jahae | - |
dc.contributor.author | Kim, Heeyoung | - |
dc.contributor.author | Park, Seol Hoon | - |
dc.contributor.author | Park, Jisun | - |
dc.contributor.author | Park, Hye Lim | - |
dc.contributor.author | Oh, So Won | - |
dc.contributor.author | Won, Kyoung Sook | - |
dc.contributor.author | Ryu, Young Hoon | - |
dc.contributor.author | Yoon, Joon-Kee | - |
dc.contributor.author | Lee, Soo Jin | - |
dc.contributor.author | Lee, Jong Jin | - |
dc.contributor.author | Chong, Ari | - |
dc.contributor.author | Jeong, Young Jin | - |
dc.contributor.author | Jeong, Ju Hye | - |
dc.contributor.author | Cho, Young Seok | - |
dc.contributor.author | Cho, Arthur | - |
dc.contributor.author | Cheon, Gi Jeong | - |
dc.contributor.author | Choi, Eun Kyoung | - |
dc.contributor.author | Hwang, Jae Pil | - |
dc.contributor.author | Bae, Sang Kyun | - |
dc.date.accessioned | 2021-08-11T08:37:26Z | - |
dc.date.available | 2021-08-11T08:37:26Z | - |
dc.date.issued | 2020-03 | - |
dc.identifier.issn | 1619-7070 | - |
dc.identifier.issn | 1619-7089 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/3056 | - |
dc.description.abstract | Purpose We investigated whether predictive clinicopathologic factors can be affected by different response criteria and how the clinical usefulness of radioactive iodine (RAI) therapy should be evaluated considering variable factors in patients with differentiated thyroid carcinoma (DTC). Methods A total of 1563 patients with DTC who underwent first RAI therapy after total or near total thyroidectomy were retrospectively enrolled from 25 hospitals. Response to therapy was evaluated with two different protocols based on combination of biochemical and imaging studies: (1) serum thyroglobulin (Tg) and neck ultrasonography (US) and (2) serum Tg, neck US, and radioiodine scan. The responses to therapy were classified into excellent and non-excellent or acceptable and non-acceptable to minimize the effect of non-specific imaging findings. We investigated which factors were associated with response to therapy depending on the follow-up protocols as well as response classifications. Multivariate logistic regression analysis was performed to identify factors significantly predicting response to therapy. Results The proportion of patients in the excellent response group significantly decreased from 76.5 to 59.6% when radioiodine scan was added to the follow-up protocol (P < 0.001). Preparation method (recombinant human TSH vs. thyroid hormone withdrawal) was a significant factor for excellent response prediction evaluated with radioiodine scan (OR 2.129; 95% CI 1.687-2.685; P < 0.001) but was not for other types of response classifications. Administered RAI activity, which was classified as low (1.11 GBq) or high (3.7 GBq or higher), significantly predicted both excellent and acceptable responses regardless of the follow-up protocol. Conclusions The clinical impact of factors related to response prediction differed depending on the follow-up protocol or classification of response criteria. A high administered activity of RAI was a significant factor predicting a favorable response to therapy regardless of the follow-up protocol or classification of response criteria. | - |
dc.format.extent | 11 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Springer Verlag | - |
dc.title | Clinicopathologic risk factors of radioactive iodine therapy based on response assessment in patients with differentiated thyroid cancer: a multicenter retrospective cohort study | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1007/s00259-019-04634-8 | - |
dc.identifier.wosid | 000517882500011 | - |
dc.identifier.bibliographicCitation | European Journal of Nuclear Medicine and Molecular Imaging, v.47, no.3, pp 561 - 571 | - |
dc.citation.title | European Journal of Nuclear Medicine and Molecular Imaging | - |
dc.citation.volume | 47 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 561 | - |
dc.citation.endPage | 571 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.relation.journalWebOfScienceCategory | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.subject.keywordPlus | ASSOCIATION MANAGEMENT GUIDELINES | - |
dc.subject.keywordPlus | RADIOIODINE REMNANT ABLATION | - |
dc.subject.keywordPlus | ADULT PATIENTS | - |
dc.subject.keywordPlus | PAPILLARY | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | NODULES | - |
dc.subject.keywordAuthor | Differentiated thyroid carcinoma | - |
dc.subject.keywordAuthor | Radioactive iodine therapy | - |
dc.subject.keywordAuthor | Recombinant human thyrotropin | - |
dc.subject.keywordAuthor | Response to therapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.